Patents by Inventor Vincent A. Pollack

Vincent A. Pollack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen
    Publication number: 20170267750
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: March 22, 2017
    Publication date: September 21, 2017
    Inventors: Kam Fai Tse, Vincent A. Pollack, John MacDougall, Suresh G. Shenoy, Traci Mansfield, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle
  • Antibodies Directed To GPNMB And Uses Thereof
    Publication number: 20160311919
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Application
    Filed: February 25, 2016
    Publication date: October 27, 2016
    Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • Antibodies Directed to GPNMB and Uses Thereof
    Publication number: 20150044212
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 12, 2015
    Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • Antibodies directed to GPNMB and uses thereof
    Patent number: 8846873
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: September 30, 2014
    Assignees: Celldex Therapeutics, Inc., Amgen Fremont, Inc.
    Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael Jeffers, William LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • ANTIBODIES DIRECTED TO GPNMB AND USES THEREOF
    Publication number: 20130244255
    Abstract: The present invention relates to antibodies with specificity to GPNMB, and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides biomarkers for evaluating the effects of therapeutic methods and uses of the antibodies with specificity to GPNMB.
    Type: Application
    Filed: February 7, 2012
    Publication date: September 19, 2013
    Inventors: Vincent A. Pollack, William LaRochelle
  • Antibodies Directed To GPNMB And Uses Thereof
    Publication number: 20130022597
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 24, 2013
    Inventors: Meina Liang, Orit Foord, Scott Klakamp, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael Jeffers, William LaRochelle, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • Method of immunodiffusion
    Patent number: 3947250
    Abstract: A method of immunodiffusion for determination of proteins of low concentration in biological fluids employing a gel medium containing 2.5-5% block copolymer of ethylene oxide and polyoxypropylene polymer.
    Type: Grant
    Filed: June 21, 1974
    Date of Patent: March 30, 1976
    Assignee: Baxter Laboratories, Inc.
    Inventor: Vincent A. Pollack